Expanding Access and Optimizing the Use of CAR T-Cell Therapy in Multiple Myeloma

Panelists discuss how pivotal trials and real-world evidence have reinforced CAR T-cell therapy’s high response rates, deep remissions, and durable outcomes in relapsed/refractory multiple myeloma.